Literature DB >> 11286650

Management and Prevention of Clostridium difficile-Associated Diarrhea.

William P. Ciesla1, David A. Bobak.   

Abstract

Clostridium difficile is a major cause of antibiotic-associated diarrhea. While treatment regimens for C. difficile have been available for decades, they remain less than optimal due to the frequent recurrences that occur after therapy is completed. Moreover, the morbidity and expense associated with C. difficile have underscored the need for more effective preventive measures than are currently available. In this review, we outline the current recommendations for treatment and prevention of C. difficile infection and, highlight some promising new approaches that may help to control this common nosocomial pathogen in the future.

Entities:  

Year:  2001        PMID: 11286650     DOI: 10.1007/s11908-996-0032-6

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  57 in total

1.  Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii.

Authors:  M Niault; F Thomas; J Prost; F H Ansari; P Kalfon
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

Review 2.  Large clostridial cytotoxins--a family of glycosyltransferases modifying small GTP-binding proteins.

Authors:  C von Eichel-Streiber; P Boquet; M Sauerborn; M Thelestam
Journal:  Trends Microbiol       Date:  1996-10       Impact factor: 17.079

3.  Treatment of relapsing Clostridium difficile diarrhoea by administration of a non-toxigenic strain.

Authors:  D Seal; S P Borriello; F Barclay; A Welch; M Piper; M Bonnycastle
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

4.  Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.

Authors:  S S Wong; P C Woo; W K Luk; K Y Yuen
Journal:  Diagn Microbiol Infect Dis       Date:  1999-05       Impact factor: 2.803

Review 5.  Antibiotics and Clostridium difficile.

Authors:  J Freeman; M H Wilcox
Journal:  Microbes Infect       Date:  1999-04       Impact factor: 2.700

6.  Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.

Authors:  M Warny; J P Vaerman; V Avesani; M Delmée
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

7.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

8.  Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis.

Authors:  D G Teasley; D N Gerding; M M Olson; L R Peterson; R L Gebhard; M J Schwartz; J T Lee
Journal:  Lancet       Date:  1983-11-05       Impact factor: 79.321

9.  Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces.

Authors:  A Schwan; S Sjölin; U Trottestam; B Aronsson
Journal:  Scand J Infect Dis       Date:  1984

10.  Human colonic aspirates containing immunoglobulin A antibody to Clostridium difficile toxin A inhibit toxin A-receptor binding.

Authors:  C P Kelly; C Pothoulakis; J Orellana; J T LaMont
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.